By Adriano Marchese
Knight Therapeutics has agreed to acquire generics and specialty branded pharmaceutical company Paladin Pharma for 120 million Canadian dollars ($83.1 million).
The specialty pharmaceutical company said Tuesday it has entered into a definitive asset-purchase agreement with Endo Operations and Paladin Pharma for the acquisition. The upfront payment in cash will also include inventory with a value of C$20 million.
Knight said that it may also pay up to another US$15 million for reaching certain milestones.
Knight Chief Executive Samira Sakhia said the synergistic transaction adds critical mass and significantly increases the size of its Canadian business as well as in Latin America.
"The acquisition adds a portfolio of stable cash flow generating pharmaceuticals that will help fund our growth in Canada and Latin America," Sakhia said.
The transaction is expected to close sometime mid-year.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 11, 2025 08:25 ET (12:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。